All In Biotech

Drug Trial Radar · NCT06429176

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

A Phase 2a, Randomized, Placebo-Controlled, Double Blind Multiple Ascending Dose Study in Patients With Cystic Fibrosis Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jun 24, 2024

Primary completion

Oct 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
SpliSense Ltd.Industry
Sponsor type
Industry
First posted
May 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation (3849 +10kb C--\>T). The purpose of this research study is to test the safety and effectiveness of multiple doses of the study drug, SPL84. Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF. In cohorts 1-3, SPL84 will be tested as a monotherapy, and in Cohort 4, SPL84 will be tested in participants who are already stable on CFTR modulator therapy. Participants will take drug SPL84 or a placebo by inhalation every week for 9 weeks (cohorts 1-3) or 12 weeks (cohort 4) and visit the clinic approximately weekly for checkups and tests.

Conditions

  • Cystic Fibrosis

Interventions

  • SPL84Drug

    SPL84 solution for nebulization

  • PlaceboOther

    Placebo solution for nebulization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  2. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rateTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  3. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rateTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  4. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressureTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  5. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetryTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  6. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperatureTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  7. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  8. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  9. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  10. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parametersTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  11. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findingsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  12. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal pulmonary function tests resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
  13. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal immunogenicity resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

Locations

27 sites in 9 countries. Site status is shown where the registry gives one.

  • Memorial Care Long Beach Medical Center

    Long Beach, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of California Los Angeles

    Santa Monica, California · Not yet recruiting

  • National Jewish Health

    Denver, Colorado · Recruiting

  • Joe DiMaggio Children's Hospital

    Hollywood, Florida · Not yet recruiting

  • Northwestern University

    Chicago, Illinois · Not yet recruiting

  • Boston Children'S Hospital

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Not yet recruiting

  • Lenox Hill Cystic Fibrosis Center

    New York, New York · Recruiting

  • Columbia University Cystic Fibrosis Program

    New York, New York · Not yet recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Not yet recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Not yet recruiting

  • University of Utah

    Salt Lake City, Utah · Not yet recruiting

  • Inova Fairfax Hospital

    Falls Church, Virginia · Not yet recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

  • Motol University Hospital

    Prague, Czechia · Not yet recruiting

  • Centre Hospitalier Régional Universitaire (CHRU) de Montpellier

    Montpellier, France · Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • Klinikum Westbrandenburg CF Zentrum Potsdam

    Potsdam, Germany · Recruiting

  • Hadassah Mt. Scopus Hospital

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center (Beilinson Hospital)

    Petah Tikva, Israel · Recruiting

  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics

    Kaunas, Lithuania · Not yet recruiting

  • Kliniki Pulmonologii, Alergologii i Onkologii Pulmonologicznej Uniwersytetu Medycznego im.Karola Marcinkowskiego w Poznaniu

    Poznan, Poland · Not yet recruiting

  • Instytut Gruźlicy i Chorób Płuc Oddział Terenowy im. Jana i Ireny Rudników

    Rabka-Zdrój, Poland · Not yet recruiting

  • Vall d'Hebron Barcelona Hospital Campus

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.